ARROWHEAD PHARMACEUTICALS, INC.
For the period ended Dec 31, 2025. Filed Feb 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Dec 31, 2025 · Filed Feb 5, 2026
ARWR$49.00-0.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Income (Loss)
(in thousands, except per share amounts)
| Three Months Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Revenue | $264,033 | $2,500 |
| Operating expenses: | ||
| Research and development | 177,203 | 137,002 |
| General and administrative | 46,021 | 26,910 |
| Total operating expenses | 223,224 | 163,912 |
| Operating income (loss) | 40,809 | (161,412) |
| Other (expense) income: | ||
| Interest income | 9,690 | 7,602 |
| Interest expense | (22,505) | (21,646) |
| Other, net | 277 | 341 |
| Total other expense | (12,538) | (13,703) |
| Income (loss) before income tax expense and noncontrolling interest | 28,271 | (175,115) |
| Income tax expense | 29 | 103 |
| Net income (loss) including noncontrolling interest | $28,242 | $(175,218) |
| Net loss attributable to noncontrolling interest, net of tax | (2,569) | (2,133) |
| Net income (loss) attributable to Arrowhead Pharmaceuticals, Inc. | $30,811 | $(173,085) |
| Net income (loss) per share attributable to Arrowhead Pharmaceuticals, Inc.: | ||
| Basic | $0.22 | $(1.39) |
| Diluted | $0.22 | $(1.39) |
| Weighted-average shares used in calculating | ||
| Basic | 137,039 | 124,848 |
| Diluted | 140,706 | 124,848 |
| Other comprehensive income (loss), net of tax: | ||
| Unrealized gains (losses) on available-for-sale securities | 146 | (507) |
| Foreign currency translation adjustments | 110 | (106) |
| Comprehensive loss attributed to noncontrolling interest | $(2,569) | $(2,133) |
| Other comprehensive income (loss) | $28,498 | $(175,831) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.